^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + nafamostat (TMPRSS2 inhibitor, Serine protease inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
Published date:
12/07/2021
Excerpt:
We, therefore, evaluated the use of combined NM and PAL, a CDK4/6 inhibitor, for overcoming endocrine resistance in ERPBCs....The viability of MCF7-TamR and MCF7-FulR cells was synergistically inhibited by combination treatment with NM and PAL (Fig. 5B). Cotreatment with NM and PAL also synergistically caused apoptosis of MCF7-TamR and MCF7-FulR cells (Fig. 5C and D).
DOI:
10.1016/j.tranon.2021.101302
